| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.24 | 0.02 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.02 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |